Halozyme Therapeutics, Inc. (HALO) 2015年年度报告「NASDAQ」.pdf

1、2015annual reportWE ARE HALOZYME.Halozyme entered 2015 with a sharp focus on our two value-creating pillars and during the course of the year executed well against our plans.My conviction has never been stronger regarding the quality of our science and the potential to create long-term value for sha

2、reholders and employees as we invest behind this two-pillar strategy to develop world-class oncology therapies for patients.The first pillar is our oncology business,with our investigational drug,PEGPH20,at the core.PEGPH20 temporarily degrades or breaks down hyaluronan,or HA,a glycosaminoglycan or

3、chain of natural sugars in the body that accumulate around certain tumors and can increase the pressure in and around the tumor,constrict the tumor vasculature and limit access of cancer therapies getting to the tumor to combat the disease.We are evaluating the ability of PEGPH20 to increase the eff

4、ectiveness of co-administered cancer treatments in pancreatic,non-small cell lung and gastric cancer patients,but see broader potential applicability for its use in multiple tumor types in combination with immuno-oncology agents,monoclonal antibodies and chemotherapies.Our work in oncology is funded

5、 in part by the second pillar of our strategy,which is centered on our licensing agreements with marquee partners,including Roche,Baxalta,Pfizer,Janssen,AbbVie and Lilly.These partners co-formulate or co-administer their therapies with our ENHANZE technology platform,which temporarily degrades HA un

6、der the skin to enable larger fluid volumes or molecules to be delivered with a subcutaneous injection or on a less frequent dosing schedule.Both ENHANZE and PEGPH20 are based on our proprietary rHuPH20 enzyme.We believe in the potential of both pillars and have multiple 2015 highlights to celebrate